NovaBay Pharma (NBY) reported Q3 EPS of ($0.10), $0.07 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $3.83 million versus the consensus estimate of $3.75 million.
NovaBay Pharma (NBY) reported Q3 EPS of ($0.10), $0.07 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $3.83 million versus the consensus estimate of $3.75 million.